# Emanuel Timor

> Emanuel Timor is a Series A investor at Vertex Ventures Israel backing Software. See 51 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vertex Ventures Israel](https://shizune.co/investors/profile/vertex-ventures-israel)
- Location: Tel Aviv, Israel
- Total investments: 51
- Last investment: Mar 2025
- Lead investor: 31%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/emanuel-timor/0/59/799

Emanuel Timor is a Board Member at Nucleai, Adaptive Shield, Zencity, Codefresh and Cymulate and General Partner at Vertex Venture Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 10 | 20% |
| Information Technology | 7 | 14% |
| Manufacturing | 5 | 10% |
| Machine Learning | 5 | 10% |
| Artificial Intelligence | 5 | 10% |

55 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 16 | 31% |
| Series B | 9 | 18% |
| Series C | 7 | 14% |
| Series D | 4 | 8% |
| Seed | 3 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 16 | 31% |
| United States | 7 | 14% |
| Canada | 2 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Navina | Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.Born from the vision of replacing the time-consuming chaos of patient data with a logical, actionable platform, Navina enables physicians to assess even the most complex cases in minutes. Its technology restructuresdisorganized data into an intelligible patient portrait, intuitively organized to support sophisticated and empathetic patient care. By leveraging AI and machine learning, the platform ensures that the most important information is immediately clear, diagnostically linked, and contextually surfaced, providing physicians with a comprehensive view of each patient’s data.The result is improved patient wellness and enhanced financial performance for both providers and payers. Navina is also a partner of the American Academy of Family Physicians (AAFP) Innovation Lab. | $55M | Series C | Mar 25, 2025 |  |
| Navina | Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.Born from the vision of replacing the time-consuming chaos of patient data with a logical, actionable platform, Navina enables physicians to assess even the most complex cases in minutes. Its technology restructuresdisorganized data into an intelligible patient portrait, intuitively organized to support sophisticated and empathetic patient care. By leveraging AI and machine learning, the platform ensures that the most important information is immediately clear, diagnostically linked, and contextually surfaced, providing physicians with a comprehensive view of each patient’s data.The result is improved patient wellness and enhanced financial performance for both providers and payers. Navina is also a partner of the American Academy of Family Physicians (AAFP) Innovation Lab. | $22M | Series B | Oct 27, 2022 |  |
| Cymulate | For companies wanting to assure their security resilience against the evolving threat landscape. Cymulate SaaS-based Extended Security Posture Management (XSPM) automates end-to-end risk assessment, thus challenging, assessing, and optimizing their cyber-security posture simply and continuously. Cymulate gives security professionals visibility toknow, control and remediate their dynamic environment. | $70M | Series D | Sep 06, 2022 |  |
| Nucleai | Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy and improving patient care. Nucleai works with leading pharmaceutical companies,licensing its research platform for internal use, and collaborating in biomarkers discovery projects. | $33M | Series B | Mar 22, 2022 |  |
| Aporia | Aporia is a self-serve monitoring platform for machine learning. Data science teams use Aporia to easily build their own customizable ML monitoring system for greater visibility into their models in production. With over 50 different monitoring types, on-prem and native cloud deployment, Aporia is the preferred ML monitoring solution for earlydetection of concept drift, data integrity issues, and performance degradation. | $25M | Series A | Feb 22, 2022 |  |
| SiteAware | SiteAware solves quality control for construction exterior by transforming physical inspections performed on the jobsite into a digital, cloud based automated processes. Siteaware's online and continuous quality conformation technology and analytics enables timely correction of errors and omissions that eliminate costly rework and projectdelays. Real estate developers and their providers can make data-driven decisions that enable higher performance, better quality and improved profitability with lower risk to workers. | $15M | Series B | Jan 26, 2022 |  |
| Navina | Navina develops an AI-driven platform that restructures patient data into intuitive patient portraits for better diagnoses and care.Born from the vision of replacing the time-consuming chaos of patient data with a logical, actionable platform, Navina enables physicians to assess even the most complex cases in minutes. Its technology restructuresdisorganized data into an intelligible patient portrait, intuitively organized to support sophisticated and empathetic patient care. By leveraging AI and machine learning, the platform ensures that the most important information is immediately clear, diagnostically linked, and contextually surfaced, providing physicians with a comprehensive view of each patient’s data.The result is improved patient wellness and enhanced financial performance for both providers and payers. Navina is also a partner of the American Academy of Family Physicians (AAFP) Innovation Lab. | $15M | Series A | Oct 18, 2021 |  |
| Adaptive Shield | Adaptive Shield is a developer of a security posture management platform that helps businesses manage their cloud services. Its services provide a continuous, automated solution, and built-in knowledge base to not only make SaaS security possible but to enable organizations to adopt practices, security frameworks, and benchmarks. | $30M | Series A | Oct 05, 2021 |  |
| Zencity | Zencity uses AI and big data to reinvent the way local governments make decisions. Its platform helps cities, counties, and other government agencies understand their residents' real needs and priorities, eliminating the guesswork from policymaking. Together with our government partners, Zencity is setting a new standard for performancemanagement in local government.With minimal integration or overhead, Zencity gathers and analyzes millions of resident-generated feedback points from online and offline channels. Then, using advanced AI and machine learning, Zencity distills reliable, actionable insights from this data. Local governments use Zencity’s insights to better prioritize resources, track performance more effectively, and - perhaps most importantly - connect more deeply with their communities. | $30M | Venture - Series Unknown | Jun 29, 2021 |  |
| Cymulate | For companies wanting to assure their security resilience against the evolving threat landscape. Cymulate SaaS-based Extended Security Posture Management (XSPM) automates end-to-end risk assessment, thus challenging, assessing, and optimizing their cyber-security posture simply and continuously. Cymulate gives security professionals visibility toknow, control and remediate their dynamic environment. | $45M | Series C | May 05, 2021 |  |

10 of 51 investments shown.

## Co-investors
- [Vertex Ventures Israel](https://shizune.co/investors/profile/vertex-ventures-israel) — VC Fund, 24 deals together
- [Vertex Ventures](https://shizune.co/investors/profile/vertex-ventures) — VC Fund, 9 deals together
- [Grove Ventures](https://shizune.co/investors/profile/grove-ventures) — VC Fund, 6 deals together
- [Walden Israel Venture Capital](https://shizune.co/investors/profile/walden-israel-venture-capital) — VC Fund, 6 deals together
- [Susquehanna Growth Equity](https://shizune.co/investors/profile/susquehanna-growth-equity) — VC Fund, 5 deals together
- [Amiti Ventures](https://shizune.co/investors/profile/amiti-ventures) — VC Fund, 4 deals together

## About Vertex Ventures Israel

VC Fund · Tel Aviv, Israel

Over the past 22 years, we backed more than 120 Israeli tech companies and overseen more than 40 exits. We focus on early-stage companies from Seed stage to B round who aim to disrupt large markets across several categories and verticals. From inception through growth, our team has been fortunate to work with some of Israel’s leadingentrepreneurs and be an early investor in 3 of the 10 largest VC stories out of Israel in the last decade: Waze (acquired by Google for $1.3B); CyberArk (IPO, $1B+); and SolarEdge (IPO, $1B+). In addition to Israel, the Vertex Global Network of funds is active in Silicon Valley, China, Singapore and India, providing a unique platform for our portfolio companies to realize their full potential by leveraging the combined experience and resources of our extensive network.

5 contacts available at Vertex Ventures Israel.

| Name | Title | Profile |
| --- | --- | --- |
| Aviad Ariel | General Partner | https://shizune.co/investors/profile/aviad-ariel |
| David Heller | General Partner | https://shizune.co/investors/profile/david-heller |
| Emanuel Timor | General Partner | https://shizune.co/investors/profile/emanuel-timor |
| Ran Gartenberg | General Partner & CFO | https://shizune.co/investors/profile/ran-gartenberg |
| Tami Bronner | Partner | https://shizune.co/investors/profile/tami-bronner-094a |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Emanuel Timor invest in?

Emanuel Timor invests primarily in Software, Information Technology and Manufacturing startups, most often at Series A and Series B stage. Most of the 51 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Emanuel Timor last invest?

The most recent investment recorded for Emanuel Timor closed in Mar 2025. Shizune tracks 51 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co